Park J S, Hwang E S, Park S N, Ahn H K, Um S J, Kim C J, Kim S J, Namkoong S E
Division of Gynecologic Oncology, Catholic Cancer Center, Seoul, Korea.
Gynecol Oncol. 1997 Apr;65(1):121-9. doi: 10.1006/gyno.1996.4596.
It is known that E2 protein of oncogenic human papillomavirus (HPV) inhibits the expression of E6 and E7 genes from their major promoters in vitro and suppresses the proliferation of cervical cancer cells. This suggests that the loss of functional E2 gene may provide selective advantages in the development of cervical cancer. Investigation of the relationship between the disruption of HPV-16/18 E2 genes by DNA integration and clinical outcome of cervical cancer may not only help to understand the mechanism of HPV-related cervical carcinogenesis, but may also provide novel management of cervical cancer. It was noted that integrated HPV-16/18 DNA was predominant in most patients with cervical cancers, marking 51 of a total of 68 cases (75%); episomal HPV DNAs were found in 5 cases (7.4%), and finally mixed forms of HPV DNAs with episome and integration were found in 12 cases (17.6%). Whole portions of E2 DNA of HPV-16 could be amplified by PCR in 19 (36.5%) of 52 cases of cervical intraepithelial neoplasia. It was shown that there was not statistically significant association with the different stages, but integrated HPV DNAs were detectable only in the patients with far-advanced stage of cervical cancers, which also means no episomal forms were detected. Episomal forms of HPV DNA were detectable in 14 (25.9%) of 54 squamous cell carcinomas (4 pure episomal forms and 10 mixed forms), whereas only 1 (8.3%) of 12 adenocarcinomas and adenosquamous cell carcinomas contained episomal viral DNA. When HPV DNA forms were compared with initial tumor size, lymphovascular space involvement, and frequency of nodal metastasis, statistically significant relationships were not found. The association of DNA integration with invasive cervical cancers was seen regardless of HPV type; however, there were differences between the integration profiles of HPV-16 and HPV-18 DNA. Of the 51 HPV-16-containing cancers, 36 (70.6%) revealed purely integrated HPV DNA, and another 10 cases (19.6%) displayed both integrated and episomal HPV DNAs. However, 5 (9.8%) cases showed only episomal copies of the HPV-16 genome. In contrast, all 17 HPV-18-containing cancers (5 cases positive for HPV-18 and 12 cases positive for both HPV-16 and -18) revealed only the integrated form of HPV-18 DNA. The expression of E6 and E7 transcripts of HPV-16/18 is uniformly correlated with the physical status of HPV DNAs. HPV E2 mRNAs were constantly expressed in the presence of the intact virus in cases with episome and mixed forms of HPV DNA. In general, amplified signals from HPV E2 RT-PCR are more intensive than those from DNA-PCR in the same patients. It is suggested that RT-PCR is a valuable method to evaluate dynamic expression of the specific gene and seems to be more sensitive than the DNA-PCR method in detecting intact E2 gene because of the gene copy numbers.
已知致癌性人乳头瘤病毒(HPV)的E2蛋白在体外可抑制E6和E7基因从其主要启动子的表达,并抑制宫颈癌细胞的增殖。这表明功能性E2基因的缺失可能在宫颈癌的发生发展中提供选择性优势。研究HPV - 16/18 E2基因通过DNA整合的破坏与宫颈癌临床结局之间的关系,不仅有助于理解HPV相关宫颈癌发生的机制,还可能为宫颈癌提供新的治疗方法。值得注意的是,整合型HPV - 16/18 DNA在大多数宫颈癌患者中占主导地位,在68例患者中共51例(75%);游离型HPV DNA在5例患者中被发现(7.4%),最后在12例患者中发现了游离型和整合型混合形式的HPV DNA(17.6%)。52例宫颈上皮内瘤变患者中有19例(36.5%)可通过PCR扩增出HPV - 16的完整E2 DNA片段。结果显示,其与不同分期无统计学显著关联,但仅在晚期宫颈癌患者中可检测到整合型HPV DNA,这也意味着未检测到游离型。54例鳞状细胞癌中有14例(25.9%)可检测到游离型HPV DNA(4例为单纯游离型,10例为混合型),而12例腺癌和腺鳞癌中仅1例(8.3%)含有游离型病毒DNA。当比较HPV DNA形式与初始肿瘤大小、脉管间隙受累情况及淋巴结转移频率时,未发现统计学显著相关性。无论HPV类型如何,均可观察到DNA整合与浸润性宫颈癌的关联;然而,HPV - 16和HPV - 18 DNA的整合模式存在差异。在51例含HPV - 16的癌症中,36例(70.6%)显示为单纯整合型HPV DNA,另外10例(19.6%)同时显示整合型和游离型HPV DNA。然而,5例(9.8%)仅显示HPV - 16基因组的游离型拷贝。相比之下,所有17例含HPV - 18的癌症(5例HPV - 18阳性,12例HPV - 16和 - 18均阳性)仅显示HPV - 18 DNA的整合形式。HPV - 16/18的E6和E7转录本的表达与HPV DNA的物理状态一致相关。在游离型和混合型HPV DNA的病例中,在完整病毒存在的情况下HPV E2 mRNA持续表达。一般来说,同一患者中HPV E2 RT - PCR的扩增信号比DNA - PCR的信号更强。提示RT - PCR是评估特定基因动态表达的有价值方法,并且由于基因拷贝数的原因,在检测完整E2基因方面似乎比DNA - PCR方法更敏感。